Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2016 Aug 19;8(8):244.
doi: 10.3390/toxins8080244.

A Single Dose of Viperfav(TM) May Be Inadequate for Vipera Ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation

Affiliations
Free PMC article
Case Reports

A Single Dose of Viperfav(TM) May Be Inadequate for Vipera Ammodytes Snake Bite: A Case Report and Pharmacokinetic Evaluation

Tihana Kurtović et al. Toxins (Basel). .
Free PMC article

Abstract

Viperfav(TM) is a commercial F(ab')₂ antivenom prepared against European vipers venom. It is safe and effective for treating envenomation caused by Vipera aspis and Vipera berus. Therapeutic efficacy for treating Vipera ammodytes ammodytes (V. a. ammodytes) envenoming has not been yet described, although protective efficacy has been demonstrated in preclinical studies. We report on a 32-year-old man bitten by V. a. ammodytes who was treated with Viperfav™. Viperfav™ promptly reduced local extension and improved systemic pathological signs, but 24 h after the incident a recurrence of thrombocytopenia occurred despite a favorable pharmacokinetic profile with systemic clearance (1.64 (mL·h(-1))·kg(-1)) and elimination half-life (97 h) among the highest ever reported. The recommended dose of Viperfav™ for V. aspis and V. berus bites may be inadequate for serious V. a. ammodytes envenomations. Following V. a. ammodytes bite, serial blood counts and coagulation profiles should be performed to help guide Viperfav™ treatment, along with supplemental administration as indicated.

Keywords: F(ab’)2 antivenom pharmacokinetics; Vipera ammodytes ammodytes envenomation; Viperfav™ antivenom treatment.

Figures

Figure 1
Figure 1
Platelet count and serum V. a. ammodytes venom (cV) and equine immunoglobulin F(ab’)2 fragments (cAV) concentrations in the patient bitten by V. a. ammodytes and treated with two vials of Viperfav™. Error bars represent 95% confidennce interval (CI) (n = 5).

Similar articles

See all similar articles

Cited by 1 article

References

    1. Chippaux J.P. Epidemiology of snakebites in Europe: A systematic review of the literature. Toxicon. 2012;59:1–14. doi: 10.1016/j.toxicon.2011.10.008. - DOI - PubMed
    1. Harry P., de Haro L., Asfar P., David J.M. Evaluation de I’immunotherapie anti-viperine par fragments F(ab’)2 purifies (Viperfav™) Presse Med. 1999;28:1929–1934. - PubMed
    1. De Haro L., Glaizal M., Tichadou L., Blanc-Brisset I., Hayek-Lanthois M. Asp Viper (Vipera aspis) envenomation: Experience of the Marseille Poison Centre from 1996 to 2008. Toxins. 2009;1:100–112. doi: 10.3390/toxins1020100. - DOI - PMC - PubMed
    1. Boels D., Hamel J.F., Deguigne M.B., Harry P. European viper envenomings: Assessment of Viperfav™ and other symptomatic treatments. Clin. Toxicol. 2012;50:189–196. doi: 10.3109/15563650.2012.660695. - DOI - PubMed
    1. De Haro L. Management of snakebites in France. Toxicon. 2012;60:712–718. doi: 10.1016/j.toxicon.2012.03.013. - DOI - PubMed

Publication types

MeSH terms

Feedback